IVIG in the treatment of children with acute and chronic idiopathic thrombocytopenic purpura and the autoimmune cytopenias.
IVIG has been shown to be useful in the treatment of acute and chronic ITP, immune neutropenia, and in some cases of AIHA. The mechanism of action of IVIG is owing to a number of factors, which include Fc blockade, immune modulation of T- and B-cell number and function, alterations in NK activity, and direct effects on autoantibody binding and production via the antiidiotypic antibody network. Current research efforts are directed toward elucidation of these modalities and determination of their relative importance in treating patients with immune-mediated cytopenias.
Nugent
D J
DJ
Department of Pediatrics, University of Wisconsin, Madison 53706.
D000208:Acute Disease; D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy*; D002648:Child; D002908:Chronic Disease; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009503:Neutropenia / Q000628:therapy; D011696:Purpura, Thrombocytopenic / Q000628:therapy*
D016756:Immunoglobulins, Intravenous